Evidence map›Paper›PMID 23145207›Full record

ArticleAmerican journal of translational research2012

The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner.

Cheng Wang, Xiangmin Lv, Chao Jiang, John S Davis

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. GPER limits adverse changes to CaFrontiers in physiology · 2022
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Cheng WangOlson Center for Women's Health, University of Nebraska Medical Center Omaha, NE 68198, USA ; Department of OB/GYN, University of Nebraska Medical Center Omaha, NE 68198, USA.
Xiangmin Lv
Chao Jiang
John S Davis
Nebraska Medical Center · US

Funding

GPR30 Mediated-Estrogen Action on Ovarian Physiology and Ovarian CancerR00HD059985 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, CHENG · 2012 to 2014
$716k
GPR30 Mediated-Estrogen Action on Ovarian Physiology and Ovarian CancerK99HD059985 · NICHD · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI WANG, CHENG · 2010 to 2011
$180k
NICHD NIH HHS K99 HD059985NICHD NIH HHS R00 HD059985
6 · The paper itself

Abstract

G-protein coupled estrogen receptor 1 (GPER) plays an important role in mediating estrogen action in many different tissues under both physiological and pathological conditions. G-1 (1-[4-(6-bromobenzo[1,3]dioxol-5yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta [c]quinolin-8-yl]-ethanone) has been developed as a selective GPER agonist to distinguish estrogen actions mediated by GPER from those mediated by classic estrogen receptors. In the present study, we surprisingly found that G-1 suppressed proliferation and induced apoptosis of KGN cells (a human ovarian granulosa cell tumor cell line), actions that were not blocked by a selective GPER antagonist G15 or siRNA knockdown of GPER. G-1 also suppressed proliferation and induced cell apoptosis in GPER-negative HEK-293 cells and MDA-MB 231 breast cancer cells. Our results demonstrate that G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner. G-1 may be a candidate for the development of drugs against ovarian and breast cancer.

Indexed as

breast cancerestrogen receptorsG-1G15GPR30/GPERovarian cancer

Identifiers

PMID23145207
PMCPMC3493027
OpenAlexW1789883744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.